Twist Bioscience Corporation
TWST
Classifica tra le azioni
#2193
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Prezzo delle azioni
$140.67
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$9.26B
Variazione (1 giorno)
5.97%
Variazione (1 anno)
329.66%
Paese
US
Scambia Twist Bioscience Corporation (TWST)
Categoria
Healthcare
Utile per Twist Bioscience Corporation (TWST)
Utile nel Jun 2026 TTM: $-135.85M
Secondo gli ultimi rapporti finanziari di Twist Bioscience Corporation, gli utili attuali della società sono $-135.85M. Nel 2024, la società ha registrato un utile di $-208.17M, una diminuzione rispetto a agli utili del 2023, che erano di $-203.47M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Twist Bioscience Corporation dal 2016 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-135.85M | 76.55% |
| 2025 | $-76.95M | -63.03% |
| 2024 | $-208.17M | 2.31% |
| 2023 | $-203.47M | -10.87% |
| 2022 | $-228.27M | 48.20% |
| 2021 | $-154.03M | 10.38% |
| 2020 | $-139.55M | 29.96% |
| 2019 | $-107.38M | 51.25% |
| 2018 | $-70.99M | 20.27% |
| 2017 | $-59.03M | 33.89% |
| 2016 | $-44.09M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $7.61B | -5,700.87% |
US
|
|
| $4.76B | -3,605.23% |
US
|
|
| $-252.70M | 86.01% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,320.43% |
US
|
